Renowned Creative Director Margeaux Buttner at PROPELLER for 2024.
Elite 2024 Creative Director Margeaux Buttner of PROPELLER In an industry where innovation and creativity are paramount, Margeaux Buttner has emerged as a leading figure. As the newly appointed Creative Director at PROPELLER, a forward-thinking pharmaceutical marketing agency, Buttner is set to steer the creative direction into uncharted territories. Her appointment marks a significant milestone […]
FDA Panel Recommends Approval for Guardant Health’s Colon Cancer Detection Test.
FDA Advisers Endorse Guardant Health’s Colon Cancer Screening Test In a pivotal step toward bolstering the arsenal against colorectal cancer, the advisory panel to the Food and Drug Administration (FDA) has rendered a positive recommendation for Guardant Health’s innovative colon cancer screening test. This endorsement, while not binding, paves the way for potential FDA approval […]
ASCO24: Preliminary Insights into Cancer Medication Research Outcomes
ASCO24: An Early Look at Cancer Drug Study Results The American Society of Clinical Oncology’s 2024 Conference (ASCO24) has once again illuminated the path of progress in cancer treatment, unveiling early results from a series of cutting-edge drug studies. These findings reflect a multi-faceted approach to cancer treatment, emphasizing targeted therapies, immunotherapies, and innovative combinations […]
STAT+: Cytokinetics Divests a Stake in its Cardiac Medication to Royalty Pharma for as Much as $575 Million, Diminishing Expectations of an Acquisition.
Cytokinetics Agrees to Sell Stake in Heart Drug to Royalty Pharma for Up to $575 Million In a strategic move that may dampen speculation around its potential acquisition, Cytokinetics, Inc. has entered into an agreement with Royalty Pharma, selling a portion of its royalty interest in omecamtiv mecarbil, its novel heart drug, for up to […]
Introducing the Enhanced Omnichannel: Elevating Your Unified Customer Experience
Welcome to Unified Customer Experience: The Next Level of Omnichannel In an era where the customer journey is more complex and fragmented than ever, healthcare companies are embracing a unified customer experience (UCX) as the next evolution of omnichannel marketing strategies. This approach promises to seamlessly integrate various communication channels, ensuring that customers receive a […]
Pfizer aims for additional savings with a new target of $1.5 billion in cost reductions.
Pfizer Expands Cost Cuts with New $1.5B Target In a major strategy shift aimed at boosting profitability in a post-pandemic market, Pfizer Inc. has unveiled plans to implement additional cost-cutting measures aiming to save $1.5 billion by the end of the fiscal year. This move underscores the pharmaceutical giant’s commitment to streamline operations and focus […]
CDC urges states and cities to maintain high-level flu monitoring due to avian influenza risk.
CDC Urges Local Health Authorities to Maintain Vigilant Flu Surveillance Amid Bird Flu Concerns In response to the escalating threat posed by the avian influenza, the Centers for Disease Control and Prevention (CDC) has issued a directive to state and city health departments, advising them to sustain peak flu surveillance measures. This precautionary move underscores […]
AstraZeneca Plans to Boost Sales to $80 Billion Through Expanded Cancer Drug Portfolio
AstraZeneca’s $80B Sales Plan Leans on Cancer Drug Expansion In a bold move that underscores the pharmaceutical giant’s commitment to consolidating its position at the forefront of cancer treatment, AstraZeneca has unveiled an ambitious sales plan targeting $80 billion by 2030. This strategic pivot places a significant emphasis on the expansion of its cancer drug […]
STAT+: House Panel Invites PBM Executives to Testify.
House Panel Invites PBM Executives to Testify In a significant move that could have far-reaching implications for the pharmaceutical industry and healthcare policy, executives from leading Pharmacy Benefit Managers (PBMs) have been invited to testify before a House panel. The inquiry aims to shed light on the intricate mechanics of drug pricing and the substantial […]
Biotech firm Progentos, supported by Forbion, launches with a $65 million investment for an MS medication.
Forbion-backed Biotech Progentos Debuts with $65M for MS Drug In a significant boost to the field of neurodegenerative diseases, Progentos, a newly formed biotechnology company, has secured an impressive $65 million in initial funding. This financial infusion, spearheaded by the leading European venture capital firm Forbion, positions Progentos at the forefront of developing innovative therapies […]